FY2026 EPS Estimates for Alector Increased by HC Wainwright

Alector, Inc. (NASDAQ:ALEC) – Analysts at HC Wainwright upped their FY2026 earnings per share estimates for shares of Alector in a research report issued on Wednesday, October 22nd. HC Wainwright analyst A. Fein now forecasts that the company will earn $0.16 per share for the year, up from their prior forecast of ($1.71). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Alector’s current full-year earnings is ($1.88) per share. HC Wainwright also issued estimates for Alector’s FY2027 earnings at $0.16 EPS, FY2028 earnings at ($1.40) EPS and FY2029 earnings at ($1.15) EPS.

Several other equities analysts have also recently issued reports on ALEC. Mizuho set a $1.50 price target on Alector and gave the company a “neutral” rating in a report on Wednesday. TD Cowen cut Alector from a “buy” rating to a “hold” rating in a report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Alector in a report on Friday. BTIG Research lowered shares of Alector from a “buy” rating to a “neutral” rating in a research note on Wednesday. Finally, Cowen cut shares of Alector to a “hold” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Buy rating, seven have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $3.00.

Alector Trading Up 2.0%

Shares of NASDAQ ALEC opened at $1.50 on Friday. The company has a 50-day moving average of $2.77 and a two-hundred day moving average of $1.88. Alector has a 1-year low of $0.87 and a 1-year high of $6.14. The company has a current ratio of 3.78, a quick ratio of 3.78 and a debt-to-equity ratio of 0.13. The company has a market cap of $151.82 million, a PE ratio of -1.29 and a beta of 0.99.

Alector (NASDAQ:ALEC) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. Alector had a negative return on equity of 112.06% and a negative net margin of 142.10%.The firm had revenue of $7.87 million during the quarter, compared to the consensus estimate of $2.76 million. Alector has set its FY 2025 guidance at EPS.

Insider Buying and Selling

In other Alector news, Director Paula Hammond sold 14,000 shares of Alector stock in a transaction on Tuesday, August 26th. The stock was sold at an average price of $2.36, for a total value of $33,040.00. Following the completion of the transaction, the director directly owned 74,909 shares of the company’s stock, valued at $176,785.24. The trade was a 15.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 9.70% of the stock is currently owned by company insiders.

Institutional Trading of Alector

Several large investors have recently modified their holdings of the stock. FNY Investment Advisers LLC increased its position in shares of Alector by 100.0% in the second quarter. FNY Investment Advisers LLC now owns 20,000 shares of the company’s stock worth $28,000 after purchasing an additional 10,000 shares during the period. Prudential Financial Inc. acquired a new stake in Alector during the second quarter worth about $30,000. HBK Sorce Advisory LLC bought a new position in Alector in the 3rd quarter valued at about $34,000. CWM LLC raised its position in shares of Alector by 370.7% in the 1st quarter. CWM LLC now owns 33,643 shares of the company’s stock valued at $41,000 after buying an additional 26,495 shares in the last quarter. Finally, Hamilton Lane Advisors LLC acquired a new position in shares of Alector in the 3rd quarter valued at approximately $43,000. 85.83% of the stock is owned by institutional investors and hedge funds.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.